{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:14:23Z","timestamp":1775002463736,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1009"],"award-info":[{"award-number":["23FC1009"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","award":["JP22K07505"],"award-info":[{"award-number":["JP22K07505"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006004","name":"Tohoku University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006004","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010391","name":"Tokyo Women's Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106706","type":"journal-article","created":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T14:25:19Z","timestamp":1756045519000},"page":"106706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Satralizumab treatment in neuromyelitis optica spectrum disorder: effects on relapse, pain, and other medications used: a retrospective chart review"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1197-1705","authenticated-orcid":false,"given":"Ryotaro","family":"Ikeguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-1400","authenticated-orcid":false,"given":"Yuko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Todo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106706_bib0001","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1212\/NXI.0000000000000640","article-title":"Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence","volume":"7","author":"Akaishi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106706_bib0002","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200266","article-title":"Interleukin-6 signaling blockade induces regulatory plasmablasts in neuromyelitis optica spectrum disorder","volume":"11","author":"Akatani","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106706_bib0003","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106706_bib0004","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/NXI.0000000000000985","article-title":"Pain, depression, and quality of life in neuromyelitis optica spectrum disorder: a cross-sectional study of 166 AQP4 antibody-seropositive patients","volume":"8","author":"Ayzenberg","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106706_bib0005","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1007\/s00198-016-3646-z","article-title":"Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis","volume":"27","author":"Balasubramanian","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.msard.2025.106706_bib0006","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11910-023-01289-9","article-title":"Polypharmacy in multiple sclerosis: prevalence, risks, and mitigation strategies","volume":"23","author":"Chapman","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2025.106706_bib0007","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106706_bib0008","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106706_bib0009","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/WCO.0000000000000960","article-title":"Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis","volume":"34","author":"Hartung","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2025.106706_bib0010","article-title":"Long-term efficacy and safety of rituximab in the treatment of neuromyelitis optica spectrum disorder","volume":"10","author":"Hayes","year":"2024","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106706_bib0011","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106706_bib0012","doi-asserted-by":"crossref","first-page":"e1018","DOI":"10.1212\/NXI.0000000000000947","article-title":"Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies","volume":"8","author":"Kim","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106706_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101907","article-title":"Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody","volume":"39","author":"Kojima","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106706_bib0014","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106706_bib0015","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.msard.2025.106706_bib0016","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10654-016-0167-1","article-title":"Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study","volume":"31","author":"Movahedi","year":"2016","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.msard.2025.106706_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105502","article-title":"Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: results from a Japanese claims database","volume":"84","author":"Nakashima","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106706_bib0018","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","article-title":"Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays","volume":"287","author":"Phuan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.msard.2025.106706_bib0019","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in Aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106706_bib0020","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-positive Neuromyelitis Optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106706_bib0021","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2025.106706_bib0022","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis Optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106706_bib0023","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/13524585231154251","article-title":"A spoonful of sugar: the risks of negative health outcomes of polypharmacy in MS is a bitter reality","volume":"29","author":"Roman","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106706_bib0024","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1093\/rheumatology\/keaa850","article-title":"Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis","volume":"60","author":"Roubille","year":"2021","journal-title":"Rheumatol. (Oxf.)"},{"key":"10.1016\/j.msard.2025.106706_bib0025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106706_bib0026","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jneuroim.2018.03.017","article-title":"Anti-IL-6 receptor antibody improves pain symptoms in mice with experimental autoimmune encephalomyelitis","volume":"319","author":"Serizawa","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106706_bib0027","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fneur.2019.00341","article-title":"Anti-IL-6 receptor antibody inhibits spontaneous pain at the pre-onset of experimental autoimmune encephalomyelitis in mice","volume":"10","author":"Serizawa","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106706_bib0028","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106706_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102750","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Takai","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106706_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2023.1234572","article-title":"Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration","volume":"4","author":"Thakolwiboon","year":"2023","journal-title":"Front. Aging"},{"key":"10.1016\/j.msard.2025.106706_bib0031","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jns.2005.08.006","article-title":"Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis","volume":"239","author":"Tortorella","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106706_bib0032","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106706_bib0033","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"Relapses in multiple sclerosis are age- and time-dependent","volume":"79","author":"Tremlett","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106706_bib0034","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.2169\/internalmedicine.9036-21","article-title":"Complete relief of painful tonic seizures in neuromyelitis optica spectrum disorder by satralizumab treatment","volume":"61","author":"Uzawa","year":"2022","journal-title":"Intern. Med."},{"key":"10.1016\/j.msard.2025.106706_bib0035","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209992","article-title":"Prevalence of, and disability due to, multiple sclerosis and neuromyelitis optica spectrum disorder in Japan by the fifth nationwide survey","volume":"103","author":"Watanabe","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106706_bib0036","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106706_bib0037","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106706_bib0038","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106706_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103772","article-title":"Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: a case series","volume":"61","author":"Yamamura","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106706_bib0040","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s10072-021-05609-0","article-title":"Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors","volume":"43","author":"Zhang","year":"2022","journal-title":"Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:18:33Z","timestamp":1774999113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":40,"alternative-id":["S2211034825004481"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106706","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Satralizumab treatment in neuromyelitis optica spectrum disorder: effects on relapse, pain, and other medications used: a retrospective chart review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106706"}}